trial

Ziprasidone in the Psychosis Prodrome

NCTId NCT00635700
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 51 (actual)
Sponsored by Yale University
Primary completion 2012-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
51 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2008-03
Primary completion
2012-11
Eligibility
ALL · 16 Years · 40 Years

Interventions & indications

Drugs
Ziprasidone

Sponsors

Yale UniversityLead Sponsor

Investigators

1
Scott W. Woods, MDPrincipal Investigator

Sites

11 total
La Jolla, United StatesLos Angeles, United StatesSan Francisco, United StatesNew Haven, United StatesAtlanta, United StatesBoston, United StatesWorcester, United StatesDetroit, United StatesGlen Oaks, United StatesChapel Hill, United StatesCalgary, Canada

Linked catalysts

1
Ziprasidone in the Psychosis Prodrome — primary completion2012-11

Facts & assertions

4 sourced
Enrollment
51
Phase
PHASE2
Primary Completion Date
2012-11
Status
COMPLETED
relationships
The graph out of here
drug
Ziprasidone
drug
lead_sponsor
Yale University
company
indication
Psychosis Prodrome
indication
Schizophrenia
indication
Psychotic Disorders
indication
investigator
Scott W. Woods, MD
person